Jonathan Andrews
Optometrist · New Holland, PANPI 1821400664
Payments from drug & device makers
Across 168 payments — averaging $34.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$1K
- Bausch & Lomb Americas Inc.$1K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$723
- AbbVie$403
- Coopervision Inc.$400
- Sun Pharmaceutical Industries Inc.$303
- plus $1K from 17 others
What the payments were for
- Consulting fees$1,02518%
- Travel & lodging$50%
- Food & beverage$4,78382%
- Gifts$371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 18 | $1,374 |
| Bausch & Lomb Americas Inc. | 26 | $1,176 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $723 |
| AbbVie(2 entities) | 17 | $403 |
| Coopervision Inc. | 14 | $400 |
| Sun Pharmaceutical Industries Inc. | 12 | $303 |
| Johnson & Johnson Vision Care, Inc. | 10 | $209 |
| Amgen(2 entities) | 3 | $175 |
| Kala Pharmaceuticals, Inc. | 5 | $145 |
| Alcon | 7 | $123 |
| Biotissue Holdings Inc. | 7 | $122 |
| Pfizer | 8 | $120 |
| Shire North American Group Inc | 2 | $118 |
| Dompe US, Inc. | 3 | $96 |
| Oyster Point Pharma, Inc. | 4 | $87 |
| Astellas Pharma US Inc | 2 | $61 |
| Novartis | 4 | $58 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $39 |
| Thea Pharma Inc. | 2 | $38 |
| Carl Zeiss Meditec USA, Inc. | 1 | $26 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFUSE$641
- BIOTRUE ONE DAY$615
- ULTRA$276
- BTOD$151
- BIOTRUE$125
- MyDay Contact Lens$125
- TEPEZZA$125
How this compares
$5,850 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 26 | $48,733 |
| LumiganBimatoprost | 69 | $40,752 |
| RestasisCyclosporine | 33 | $38,633 |
| VyzultaLatanoprostene Bunod | 91 | $34,851 |
| CombiganBrimonidine Tartrate/Timolol | 59 | $22,820 |
| TyrvayaVarenicline Tartrate | 15 | $14,937 |
| RhopressaNetarsudil Mesylate | 19 | $9,246 |
| Brimonidine Tartrate | 29 | $2,393 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 145 | $2,174 |
| Latanoprost | 167 | $2,035 |
| Prednisolone Acetate | 17 | $545 |
| Doxycycline Hyclate | 11 | $513 |
| Dorzolamide Hcl | 22 | $315 |
| Timolol Maleate | 24 | $264 |
| Cephalexin | 11 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $403 | $102,205161 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,374 | $48,73326 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,176 | $34,85191 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $87 | $14,93715 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $20 | $9,24619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in New Holland
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Glenn CorbinWyomissing$426K
- Leslie O DellNew Freedom$409K
- Kevin BistlinePlymouth Meeting$302K
- Thomas KislanStroudsburg$267K
- Erick HendersonPittsburgh$266K
- Natasha HindmanCranberry Twp$179K
- Ryan YealyLancaster$164K
- Michael CymborState College$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.